Physician profile
Jonathan W Rick
NPI 1710440169
$10,946.51
in general payments reported to CMS, 2019-2025
13 companies · $9,887 in 2025
The $9,887 reported for 2025 was more than what 92% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $273 · 2024: $787 · 2025: $9,887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,950 · Travel and Lodging: $1,603 · Food and Beverage: $1,288 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,950.00 |
| Travel and Lodging | $1,603.17 |
| Food and Beverage | $1,288.08 |
| Education | $105.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $9,246.87 | 2025 | |
| Beigene, LTD. | $450.00 | 2025 | |
| Abbvie INC. | $262.75 | 2023-2024 | |
| Janssen Biotech, INC. | $255.15 | 2023-2024 | Tremfya, Simponi, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $231.47 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $151.22 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $70.33 | 2023-2024 | Olumiant, Taltz, Zepbound |
| Pfizer INC. | $62.71 | 2023-2024 | |
| Leo Pharma INC. | $50.20 | 2023-2024 | Adbry |
| Dermavant Sciences, INC. | $48.31 | 2023-2024 | Vtama |
| Kyowa Kirin, INC. | $43.74 | 2023-2025 | Poteligeo |
| Arcutis Biotherapeutics, INC. | $39.03 | 2024 | Zoryve |
| Genzyme Corporation | $34.73 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Rick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.